Quantum-Si (QSI) Q4 2024: Revenue Surges 183% as Commercial Expansion Accelerates
Quantum-Si achieved a pivotal commercial milestone with its first quarterly revenue exceeding $1 million, driven by diversified customer adoption and expanding global distribution. The company reinforced its financial position through significant capital raises, extending its cash runway into late 2027. Strategic investments in innovation and commercialization set the stage for accelerated growth and product launches in 2025.
Summary
- Commercial Diversification Advances: Customer base expanded beyond academia to include biotech, pharma, government, and contract research organizations globally.
- Innovation Roadmap Progresses: Launch of Platinum® Pro and forthcoming Proteus platform signal deepening technology leadership.
- Financial Strength Preserved: Over $86 million raised recently, securing operational runway into the second half of 2027 amid macroeconomic uncertainties.
Business Overview
Quantum-Si is a proteomics technology company specializing in next-generation protein sequencing. The company generates revenue primarily through sales of its Platinum® instruments and consumable sequencing kits, targeting academic, pharmaceutical, biotech, government, and contract research organizations. Its business model combines instrument sales with recurring consumable kit revenues, supported by software workflows and global distribution partnerships.
Performance Analysis
Quantum-Si reported fourth quarter 2024 revenue of $1.2 million, marking the first quarter surpassing $1 million in sales and representing a 52% sequential increase. Full-year revenue reached $3.1 million, a 183% year-over-year growth, reflecting successful commercialization and market penetration. Gross margins held steady at approximately 51-52%, though management cautioned variability due to product mix shifts between instruments and consumables as well as inventory accounting impacts.
Operating expenses remained essentially flat on an adjusted basis year-over-year, with $26.7 million in Q4 2024 compared to $26.3 million in Q4 2023, despite increased commercialization efforts. Research and development expenses declined 11% year-over-year, reflecting restructuring and realignment toward focused product delivery, while selling, general, and administrative expenses rose 13% driven by commercial ramp-up. Net loss widened to $33.1 million in Q4 2024 from $22.0 million a year earlier, consistent with the company’s investment phase.
- Revenue Momentum: Consistent quarter-over-quarter growth culminated in the highest quarterly revenue to date, driven by diversified end markets and geographic expansion.
- Expense Discipline: Adjusted operating expenses remained stable despite scaling commercial activities and investing in the Proteus platform development.
- Capital Position: Cash and marketable securities totaled $209.6 million at year-end, bolstered by $86 million raised through late 2024 and early 2025, extending runway into 2027.
Overall, the quarter reflects effective execution on commercialization and innovation priorities, positioning Quantum-Si for accelerated growth as new products and partnerships come online in 2025.
Executive Commentary
"We significantly diversified our customer base across multiple market segments and geographies, culminating in our first quarter exceeding $1 million in revenue and the sale of our 50th Platinum instrument."
Jeff Hawkins, President and Chief Executive Officer
"We have kept adjusted operating expenses flat year-over-year while funding commercial ramp and our game-changing Proteus development program, maintaining financial discipline to extend our cash runway into the second half of 2027."
Jeff Kyes, Chief Financial Officer
Strategic Positioning
1. Commercial Adoption and Market Diversification
Quantum-Si transitioned from a primarily academic customer base to a balanced mix including biotech, pharmaceutical, government, and contract research organizations. The company expanded its international distribution network to 18 partners, covering Western and Eastern Europe, Asia, the Middle East, Africa, South America, and the South Pacific. This broadening footprint addresses a global proteomics market underserved by legacy instruments due to cost and infrastructure barriers, with Platinum’s lower capital expense and simplified workflow providing a competitive advantage.
2. Innovation Roadmap and Product Pipeline
The launch of the Platinum® Pro instrument in January 2025 introduces enhanced processing efficiency and onboard/cloud data analysis capabilities, including a Pro Mode for custom application development. The upcoming Proteus platform, targeting a 2026 launch, promises a quantum leap in throughput with up to 160 million wells per run, enabling billions of reads and supporting de novo sequencing ambitions. Complementary consumable and software enhancements, such as the version 4 sequencing kit and ProteoView bioinformatics pipeline, further expand application breadth and proteome coverage.
3. Financial Discipline and Capital Allocation
Quantum-Si maintained adjusted operating expenses flat year-over-year despite scaling commercialization and advancing R&D. Capital raises totaling over $86 million in late 2024 and early 2025 underpin a cash runway extending into the second half of 2027. This financial strength supports continued investment in commercialization, product development, and strategic partnerships while navigating macroeconomic uncertainties, including NIH funding variability.
4. Scientific Engagement and Data Generation
The company established a dedicated scientific affairs team to collaborate with customers and key opinion leaders, accelerating publication of peer-reviewed data validating next-generation protein sequencing. Recent manuscripts demonstrate sensitivity in detecting low abundance variants, single amino acid variant quantification, and complementary use with mass spectrometry, enhancing credibility and driving adoption.
5. Channel Partner Enablement and Sales Expansion
Quantum-Si is actively training and onboarding Avantor’s North American sales force and international distribution partners, aiming for revenue contributions to scale in the second half of 2025. Internal commercial team growth and ramp-up are progressing, with most representatives now fully deployed in the field, supporting pipeline build and customer engagement.
Key Considerations
Quantum-Si’s 2024 performance reflects a critical inflection point in commercial execution and product innovation, with several factors shaping near-term and medium-term prospects:
- Commercial Execution Maturity: Elongated sales cycles remain a challenge, but consistent pipeline development and diversified end markets reduce concentration risk.
- International Market Opportunity: Lower capital cost and simplified workflows position the company well to penetrate underserved global regions without advanced proteomics infrastructure.
- Innovation Milestones: The Proteus platform’s development progress and upcoming sequencing kit launches are key value drivers, with technical milestones on track to support the 2026 launch.
- Capital Efficiency: Flat adjusted operating expenses despite increased commercial and R&D activity demonstrate disciplined capital allocation, critical for sustainability.
- External Funding Environment: NIH budget uncertainties may impact U.S. academic demand, but diversified customer segments and international growth mitigate this risk.
Risks
Quantum-Si faces execution risks related to elongated sales cycles and the challenge of scaling adoption across diverse markets. The uncertain NIH funding environment presents potential headwinds for the academic research segment in the U.S. Additionally, the company’s technology remains early in commercialization, with product mix and gross margins subject to variability. Competitive pressures from alternative proteomics technologies, including emerging nanopore approaches, represent longer-term risks. Finally, the successful development and commercialization of the Proteus platform are critical to sustaining growth trajectories.
Forward Outlook
For the first quarter of 2025, Quantum-Si anticipates revenue of at least $900,000, reflecting approximately 100% year-over-year growth while accounting for typical seasonal softness and uncertainties from NIH funding and Avantor onboarding. Adjusted operating expenses are guided to $103 million or less for the full year 2025, with total cash usage expected to be $95 million or less. The company expects Avantor to begin contributing revenue in the second quarter, with more pronounced acceleration in the back half of the year as distribution partners and internal sales teams fully ramp.
Takeaways
Quantum-Si’s fourth quarter and full year 2024 results mark a significant commercial and strategic inflection, underscored by:
- Commercial Traction: Achieving the first $1 million revenue quarter and expanding the customer base internationally validates the company’s market approach and product value proposition.
- Innovation Momentum: The Platinum Pro launch and Proteus development program position Quantum-Si to capitalize on the growing proteomics market with scalable, differentiated technology.
- Financial Resilience: Robust capital raises and disciplined expense management provide a strong financial foundation to navigate uncertainties and invest in growth.
Conclusion
Quantum-Si closed 2024 with clear commercial progress and a strengthened financial position, setting a foundation for accelerated growth through 2025. The company’s focus on expanding global reach, advancing its technology roadmap, and maintaining capital discipline aligns with its ambition to lead next-generation protein sequencing and broaden proteomics research accessibility worldwide.
Industry Read-Through
Quantum-Si’s results highlight the growing importance of scalable, cost-effective proteomics tools in life sciences research, particularly as multi-omics integration gains traction. The company’s expansion into international markets underscores a broader industry trend toward democratizing advanced research technologies beyond traditional hubs. Additionally, the emphasis on integrating AI and high-throughput sequencing aligns with the sector’s push for enhanced data generation to fuel drug discovery and precision medicine. Competitors exploring alternative sequencing modalities, such as nanopores, remain early stage, reinforcing the current opportunity for Quantum-Si’s kinetic detection approach. Investors and industry participants should monitor commercialization execution and innovation milestones closely as indicators of proteomics technology adoption trajectories.